Our aims were to explore cardiac magnetic resonance quantification of myocardial extracellular volume (ECV) in adults with repaired tetralogy of Fallot (rTOF) when compared with healthy controls and to investigate the association between ECV and major adverse cardiovascular outcomes. 
Introduction
Cardiac magnetic resonance (CMR) imaging is routinely used in the evaluation of patients with repaired tetralogy of Fallot (rTOF). 1 Segmental myocardial fibrosis is known to be present in rTOF based on histology and can be identified using CMR late gadoliniumenhanced (LGE) imaging. 2, 3 Myocardial fibrosis is associated with adverse cardiovascular outcomes and may be a substrate for arrhythmia including ventricular tachycardia (VT) in rTOF. 4 However, LGE imaging may fail to characterize diffuse interstitial changes. 5 CMR T1
mapping with calculation of the extracellular volume (ECV) fraction is an emerging technique that can be used for the evaluation of diffuse interstitial myocardial changes including fibrosis. 6, 7 The role of CMR for quantification of right ventricular (RV) extracellular volume (RVECV) measurements in relation to prediction of adverse outcomes in adults with rTOF has not been studied extensively. Although limited data are available on the predictive value of left ventricular (LV) ECV in those with rTOF, only two prior retrospective studies have investigated the differences in non-contrast and post-contrast T1 values of the RV in rTOF when compared with healthy controls. [8] [9] [10] [11] [12] Furthermore, ECV assessment is particularly challenging in the thin-walled RV, given possible contamination by adjacent blood pool or epicardial fat. The aim of this study was to explore quantification of myocardial ECV in adults with rTOF when compared with healthy controls and to investigate the association between ECV and major adverse cardiovascular outcomes.
Methods

Study population
From September 2014 to April 2017, patients with rTOF undergoing CMR were prospectively screened for study enrolment at the time of routine clinical evaluation at our institution. The study protocol was approved by the institutional research ethics board, and written informed consent was obtained from all subjects.
Inclusion criteria for study subjects included age > _18 years, history of rTOF, and clinically indicated referral for CMR with LGE. Subjects with contraindications to CMR with gadolinium were excluded. A reference healthy control cohort was identified, defined as volunteers without past medical history of cardiovascular disease based on history. 13 
CMR technique
CMR studies were performed on a 1.5-T imager (Magnetom Avanto Fit; Siemens Healthcare, Erlangen, Germany). Retrospectively gated cine steady-state free precession (SSFP) images were obtained for assessment of ventricular volumes, mass, and systolic function by a stack of short-axis slices ensuring ventricular coverage (6-8 mm slice and 2 mm inter-slice gap). Among patients, ECG-gated, free-breathing cine phase-contrast flow measurements were obtained at the main pulmonary artery for assessment of pulmonary regurgitation (PR). Myocardial fibrosis was assessed using LGE imaging and modified Look-Locker inversion recovery (MOLLI) T1 mapping. Among patients, LGE imaging was performed approximately 10 min following administration of 10 mL gadobutrol (Gadovist; Bayer Healthcare, Berlin, Germany), employing a 2D inversion recovery gradient-recalled echo sequence (slice 6-8 mm and 2 mm interslice gap) with ventricular coverage in short-axis orientation. T1 mapping was performed pre-contrast and 12-15 min post-contrast in short-axis orientation at basal, mid, and apical slice locations (TI 120-4000 ms, flip  angle 35 , field of view (FOV) 360 mm, matrix 256 Â 192, and slice thickness 6 mm). Recommended MOLLI inversion groupings were used for optimized precision: pre-contrast (5(3)3) and post-contrast (4(1)3(1)2). 14 The imaging technique used for healthy volunteers has been previously published. 13 Haematocrit was determined from a venous blood sample following the CMR study.
CMR analysis
Evaluation of cardiac volumes, function, mass, and PR flow were performed using commercial software (QMASS MR, Medis Medical Imaging Systems, Leiden, The Netherlands). RV and LV endocardial and epicardial borders were contoured on SSFP images to assess for end-diastolic and end-systolic volumes, ejection fraction, and mass by a single experienced observer, blinded to patient outcomes, in a standardized fashion according to a previously published protocol. 15 The presence of hinge-point and non-hinge-point ventricular LGE was qualitatively assessed by visual inspection of all available LGE images. 2 We evaluated for RV LGE at the superior, anterior, and inferior RV walls and LV LGE with exclusion of regions expected to enhance (such as surgical material involved in patching of the RV outflow or ventricular septal defect closure). The interventricular septum was considered part of the LV. After inline, non-rigid motion correction of individual MOLLI images, an inline T1 map was generated using standard three-parameter fitting. Analysis was performed offline using commercial software (cvi42; Circle CVI, Calgary, Canada). All T1 maps were analysed by a single experienced observer (K.H., 5 years of cardiovascular imaging experience) blinded to clinical outcomes. Regions of interest (ROIs) were drawn manually in the LV blood pool with care taken to avoid the myocardium and papillary muscles. A single ROI was drawn in the thickest anterior or inferior RV segment at the basal or mid-ventricular level with a minimal ROI size of 0.15 cm 2 , avoiding regions with artefact or LGE and ensuring that neither blood pool nor epicardial fat was included within the contour (Figure 1) . 16 If an adequately sized ROI could not be drawn reliably within myocardium meeting these criteria, the T1 map was not included in the analysis. LV endocardial and epicardial borders were manually contoured on a single mid-ventricular slice avoiding regions with evidence of LGE. Myocardial RVECV and LVECV were calculated based on pre-and postcontrast T1 values and haematocrit, as proposed by Arheden et al. 17 Elevated RVECV and LVECV were defined as 34% and 30%, respectively, based on prior published thresholds. 7, 16 To assess for inter-observer agreement of ECV values, 10 randomly selected pre-and post-contrast T1 maps were re-analysed by a second experienced imager (A.C., 15 years of cardiovascular imaging experience) who was blinded to patient identifying data and to the first set of measurements. To assess for intra-observer agreement of ECV measurements, 10 randomly selected pre-and post-contrast T1 maps were re-analysed by the first experienced imager after a minimum of 2 months interval, blinded to clinical outcomes and the first set of measurements.
Clinical data
Major adverse cardiovascular events were defined as a composite end point at the time of last follow-up including death, out-of-hospital cardiac arrest, heart failure (HF) requiring admission for escalation of therapy, and haemodynamically significant VT >30 s and/or requiring invasive therapy [ablation and/or automatic implantable cardiac defibrillator implanta- 
limited cardiopulmonary exercise testing as part of routine clinical care on a cycle ergometer (Elema, Solna, Sweden), with analysis of expiratory gases according to a previously published protocol. 18 
Statistical analysis
Statistical analysis was performed using STATA v14.1 (StataCorp, College Station, TX, USA). All continuous data were first tested for normal distribution using the Shapiro-Wilk test. Continuous variables were described using mean and standard deviation or median and IQR, and categorical variables using numbers and percentage. Comparisons between patients and controls were made by t-test for continuous values with normal distribution and Mann-Whitney rank-sum test for continuous values with non-normal distribution. Categorical variables were compared using the v 2 or the Fisher's exact test. Correlations between continuous variables were assessed with the Pearson's or Spearman's correlation coefficient. Inter-observer and intra-observer agreement was assessed via the intra-class correlation coefficient (ICC) with two-way random-effects model and coefficient of variance (COV). Cox proportional hazards analysis was used to obtain estimates of the hazard of the composite end point associated with CMR values. Adjustment for covariates in the model was limited by the number of adverse events observed. The proportionality of hazards over time was assessed by testing interactions between predictors and a continuous linear function of time. The linearity assumption was assessed for continuous variables with the addition of a quadratic term. Sensitivity analysis was performed, restricting the Cox proportional hazard analysis to patients without pulmonary valve replacement (PVR) at the time of enrolment. A two-tailed P-value <0.05 was considered statistically significant.
Results
Study population
Forty-four patients (32.9 ± 13.6 years, 59% male) and 10 healthy controls (31.5 ± 4.4 years, 50% male) were studied. Baseline characteristics are summarized in 
CMR findings
Baseline CMR findings are shown in Table 2 . RV LGE was present in 19 patients. Non-hinge-point LV LGE was present in nine patients, while hinge-point LGE was present in 27 patients. Inability to draw a reliable myocardial ROI precluded ECV assessment in eight patients and five controls. Mean pre-contrast RV T1 and RVECV values were significantly higher in patients compared with the controls (1062.3 ± 66.9 ms vs. 954.2 ± 177.7 ms, P = 0.011 and 31.5 ± 5.4% vs. 26 .3 ± 2.1%, P = 0.027, respectively), although pre-contrast LV T1 and LVECV values did not differ significantly (P = 0.139 and P = 0.941, respectively). RVECV was significantly higher than LVECV (P < 0.001). Six (15%) patients had increased LVECV and 9 (29%) patients had elevated RVECV. Correlations between RVECV and LVECV, respectively, with clinical parameters and CMR measurements are shown in Table 3 . Among patients with rTOF, RVECV was found to have a positive correlation of moderate strength with RVEDV (absolute and indexed), with RVESV (absolute and indexed) and with indexed RV mass, respectively. RVECV has a negative correlation of moderate strength with RVEF. Clinical parameters did not correlate significantly with either RVECV or LVECV.
Adverse outcomes
A major adverse cardiovascular event occurred in nine (21%) patients: death (n = 1), out-of-hospital cardiac arrest (n = 1), HF (n = 1), and VT (n = 6). Death occurred in one patient unexpectedly <30 days following PVR. The patient with the out-of-hospital cardiac arrest ultimately went on to PVR and device implantation. The patient admitted for escalation of HF therapy subsequently received a device with resynchronization and defibrillation capacities. Documented VT occurred in Figure 1 Short-axis late gadolinium-enhanced image (a) and pre-contrast T1 map (b) in a 61-year-old male with repaired tetralogy of Fallot. On the T1 map, regions of interest were drawn in the right ventricular myocardium (blue ROI, white arrow), remote from areas of late gadoliniumenhanced in the right ventricular outflow tract (red arrow) and the inferior right ventricular insertion point (orange arrow). Contours were drawn along the left ventricular endocardial (red contour) and epicardial (green contour) surfaces with care taken to avoid areas of late gadolinium enhanced.
Relationship between ECV and clinical outcomes in tetralogy of
six patients (sustained VT >30 s in five patients; one patient had recurrent, haemodynamically destabilizing non-sustained VT resulting in AICD implantation); five of these patients went on to AICD implantation and one was found to be non-inducible following preoperative mapping and intraoperative ablation.
In patients with a major adverse cardiac event, RVECV was significantly elevated when compared with those without an adverse event (35.0 ± 5.5% vs. 29 .6 ± 4.5%, P = 0.014). On univariable analysis to evaluate the relationship between CMR measurements and clinical outcomes ( Table 4) , RVECV was associated with increased risk for the composite end point [hazard ratio (HR) 1.13 , 95% confidence interval (CI) (1.01-1.28), P = 0.037]. After the analysis was restricted to patients without PVR at study entry, the association remained statistically significant between RVECV and adverse outcomes [seven events, HR 1.17, 95% CI (1.01-1.36), P = 0.038]. Indexed measures of RV volumes, indexed RV mass, and RVEF were also associated with the composite end point, whereas LVECV, indexed LV volumes, and LV systolic function were not ( Table 4) . 
Inter-and intra-observer agreement
Discussion
This prospective study is the first to demonstrate that increased RVECV is associated with major adverse cardiovascular events in adults with rTOF. When considering a surrogate marker of diffuse fibrosis, RVECV was elevated in 29% of this study population, suggesting that remodelling at the tissue level may be associated with adverse clinical outcomes. We found that the hazard of major adverse cardiovascular events increased by 13% for every 1% absolute increase in RVECV.
Only three prior studies have reported RV T1 and ECV values in rTOF, all in a retrospective fashion (see Supplementary data online, Table S1 ). Kozak et al. 10 reported that post-contrast RV and LV T1
values were lower in children with rTOF compared with the healthy controls. Post-contrast T1 values were shorter in the RV compared with the LV, suggesting a higher RV fibrotic burden. Unlike our study, RVECV retrospectively in a cohort of children and young adults with rTOF. RVECV was significantly higher in patients compared with the controls, but RVECV was not associated with arrhythmia. 18 In this study, RVECV values were slightly higher in TOF patients (34.2 ± 5.6%) and healthy controls (28.4 ± 6.3%) compared with our results (31.5 ± 5.4% and 26.3 ± 2.1%, respectively), which may be due to differences in technique. 19 We employed a strict minimum ROI size for RV T1 mapping analysis, resulting in exclusion of some cases but in doing so minimizing the potential for erroneously high ECV if adjacent structures were inadvertently included in the RV myocardial ROI. The same authors reported that increased LVECV in rTOF was associated with arrhythmia. 18 The definition of arrhythmia in this study was more encompassing than ours, including a variety of atrial arrhythmias, ventricular ectopy, and non-sustained arrhythmia (atrial or ventricular), which did not necessarily result in escalation of therapy. In contrast, our definition of arrhythmia was restricted to haemodynamically significant VT resulting in invasive therapies, including AICD implantation, and/or surgical ablation. Yim et al. 8 reported that non-contrast RV T1 values are elevated in children with rTOF and were associated with longer cross-clamp times at surgery. However, they evaluated neither RVECV nor the relationship to major adverse events. Additional reports examined LVECV values in patients with rTOF 9,11,18 with conflicting results, possibly related to differences in ages of the populations studied. While Riesenkampff et al. 11 reported no significant difference in LV non-contrast T1 and LVECV values between children with rTOF and healthy controls, Broberg et al. 9 reported that LVECV was higher in older adults with rTOF compared with the controls. In the latter study, those with increased LVECV were more likely to develop adverse events (specifically new atrial arrhythmias and cardiovascular death). The relatively young age of our adult population, the length of follow-up, a more restrictive definition of adverse outcomes, and differences in imaging technique may explain, at least in part, the lack of association between LVECV and the composite outcome in our study. Notably, previous publications have not demonstrated the association between RVECV and development of major adverse cardiovascular events in adults with rTOF, which is a strength of this study. We demonstrate that RVECV may be a predictor of major adverse events, despite our modest sample size. The principal novel findings to emerge from our study include the following:
(1) RVECV increases the hazard of major adverse cardiovascular events in adults with rTOF. (2) RVECV correlates positively with both RVEDV (absolute and indexed) and RV mass (indexed).
In line with previous studies, we found an association between RV volumes, mass, and systolic function with major adverse outcomes in the rTOF population. 20, 21 Increasingly, research efforts are focusing on what causes or mediates late onset of complications in adults with rTOF. Adverse events, including VT, HF, and sudden death, are seen with increasing frequency with advancing age, despite successful repair in early childhood. 22 Identification of non-invasive imaging markers of poor outcome are highly desirable, and standard CMR measurements of ventricular size, function, and mass have been linked to clinical compromise in a growing body of publications. 20, 21 CMR-derived ECV has been shown to correlate with histological myocardial fibrosis in other conditions and has been associated with adverse events including death and HF in non-congenital populations. 23, 24 RV non-contrast T1 and ECV values are elevated in patients without congenital heart disease (CHD) in the setting of RV dysfunction and pulmonary hypertension [25] [26] [27] [28] and correlate with pulmonary haemodynamics, RV arterial coupling, and RV function. 29 In our study, RVECV values are higher compared with LVECV values, which may be explained by higher collagen content and fibrosis of the RV. 26, 30 This finding is concordant with the results of prior studies. 10, 18 Increased RVECV has been proposed to reflect cardiomyocyte In comparison with the LV, the thin-walled RV presents unique imaging challenges. Although our methodology for RV assessment focused on sampling myocardial regions of greatest hypertrophy for assessment of diffuse fibrosis, more extensive study of the RV may yield higher fidelity results. Several techniques have been proposed to improve T1 quantification of the RV, including imaging in systole rather than diastole, and newer higher spatial resolution sequences. 10, 26, 27, 31 The results of a recent study indicate that RV T1 maps could be evaluated successfully in approximately half of the healthy controls and a larger proportion of patients with CHD, similar to our findings. 16 They report that RVECV can be assessed with T1 mapping, provided that the image quality allows for sufficient distinction between blood and myocardium and RV wall thickness is >one pixel and conclude that under these conditions RVECV measurements can be integrated into clinical practice in CHD. 16 In our analysis, a minimum RV myocardial ROI size of 0.15 cm 2 was required (>one pixel)
for inclusion, and T1 maps with insufficient distinction between blood and myocardium were not analysed (18% of rTOF and 50% of controls), in keeping with these recommendations. Furthermore, it is important to remember that generation of T1 maps requires exact co-registration of individual pixels and inconsistency in this process may further introduce error. Myocardial fibrosis in patients with TOF can be attributed to a variety of factors prior to repair (such as duration of cyanosis and exposure to pressure overload), during repair (including myocardial protection strategies and intraoperative technique), and following repair (specifically advancing age and adaptation of the ventricle to chronic volume/pressure overload). Our data demonstrate a relationship between various CMR measures, including RVECV, increased RV volume, and increased RV mass, with outcomes, underscoring a multifactorial process that likely contributes to major adverse clinical events. These observations lend support to the postulate that chronic haemodynamic sequelae following initial repair can trigger development of RV fibrosis, which may potentially mediate development of late electrical and/or mechanical complications in adults with rTOF.
The results of this study have several potential clinical implications with respect to prognosis and management. Myocardial fibrosis could be a potential target for pharmacological intervention with antifibrotic agents. Non-invasive imaging with CMR with detection of myocardial fibrosis could allow for more refined timing of interventions such as PVR. A better understanding of how ECV may improve the discrimination of traditional risk factors, such as QRS duration on ECG, RV size, and ejection fraction is highly desirable, although beyond the scope of our study.
Limitations
This study is primarily limited by the relatively small number of subjects and modest total number of adverse events. A multivariable model could not be developed with the number of patient outcomes observed, and therefore, the value of RVECV over other clinical and imaging parameters could not be determined. The cohort of patients studied does not reflect the entire spectrum of adult patients with rTOF, as patients unsuitable for CMR assessment with gadolinium were excluded. There is a potential referral bias as clinicians may refer sicker patients for CMR, although this is mitigated by the fact that CMR is used for routine clinical surveillance (typically every 2-3 years) in this population, 15, 32, 33 and the fact that patients with AICD/pacemakers were excluded. Although care was taken to draw ROIs in the RV myocardium only, partial volume averaging and contamination of T1 values from the inadvertent inclusion of blood pool or epicardial fat are potential pitfalls, which could result in artificially high ECV values, despite the relatively stringent methodology for contour definition employed.
Conclusion
Increased RVECV is associated with major adverse cardiovascular events in adults with rTOF. If myocardial fibrosis plays a role in mediating adverse outcomes, this could be a potential target for future pharmacological therapies and may allow for more refined timing of intervention. The results of this study may lead to future larger studies exploring the potential role for RVECV in risk stratification within the adult population with rTOF.
